We have created
a robust pipeline

A robust pipeline of therapeutic development programs created to address several
important patient populations.

NMX1 for Oncology
and Cardio-Oncology

Our lead program, NMX1, is a novel, patented, orally available small molecule with excellent safety and PK properties that inhibits mTOR, secretion of IL-11, and expression of CXCR4. This unique mechanism allows NMX1 to act on both the tumor and the tumor microenvironment to prevent cancer cell proliferation, invasion, and migration.  In addition, NMX1 activates AMPK, protecting the heart to prevent cardiotoxicity, inflammation, and fibrosis. NMX1 is poised to have significant potential in Triple Negative Breast Cancer (TNBC) treatment by maintaining or enhancing the superior efficacy of anthracycline therapy while mitigating its long-term cardiotoxicity.

In addition to the initial indications, the Company is evaluating NMX1 in rare pediatric cancers such rhabdomyosarcoma, osteosarcoma, and neuroblastoma.  Currently, NovoMedix is advancing NMX1 into IND-enabling studies.

NMX2 for Fibrosis

IL-11 is significantly upregulated in invasive fibroblasts in Idiopathic Pulmonary Fibrosis (IPF) and is increasingly recognized as key determinant of lung fibrosis, inflammation, and epithelial dysfunctions. NMX2 is our lead fibrosis drug candidate that prevents and reverses established fibrosis and inflammation in aggressive pre-clinical models of lung and liver fibrosis, through the inhibition of IL-11 and pro-inflammatory cytokine production. It has also shown compelling synergistic effects pre-clinically with two of the leading fibrosis drugs on the market today, Esbriet® and OFEV®. The company is currently advancing NMX-2 into IND-enabling studies.